Altamira Therapeutics Ltd. Interest Expense Income Net Defined Benefit Liability Asset
Altamira Therapeutics Ltd. (CYTOF) reported Interest Expense Income Net Defined Benefit Liability Asset of $3.71 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Interest Expense
ifrs-full:InterestExpenseIncomeNetDefinedBenefitLiabilityAsset · last filed 2025-04-30
CHF
| Period end | Interest Expense Income Net Defined Benefit Liability Asset 12 month |
|---|---|
| 2023-12-31 | 3.27K CHF 20-F/A · filed 2024-04-22 |
| 2022-12-31 | 1.57K CHF 20-F/A · filed 2024-04-22 |
| 2021-12-31 | 1.88K CHF 20-F/A · filed 2024-04-22 |
| 2020-12-31 | 2.05K CHF 20-F · filed 2023-05-16 |
| 2019-12-31 | 5.14K CHF 20-F · filed 2022-04-12 |
| 2018-12-31 | 14.54K CHF 20-F · filed 2021-03-31 |
| 2017-12-31 | 12.99K CHF 20-F · filed 2020-04-16 |
| 2016-12-31 | 14.92K CHF 20-F · filed 2019-03-14 |
| 2015-12-31 | 14.87K CHF 20-F · filed 2018-03-22 |
USD
| Period end | Interest Expense Income Net Defined Benefit Liability Asset 12 month |
|---|---|
| 2024-12-31 | $3.71K 20-F · filed 2025-04-30 |
| 2023-12-31 | $4.82K 20-F · filed 2025-04-30 |
| 2022-12-31 | $1.65K 20-F · filed 2025-04-30 |